Seres Therapeutics Inc (NAS:MCRB)
$ 0.7968 0.0209 (2.69%) Market Cap: 120.67 Mil Enterprise Value: 222.34 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 49/100

Q2 2022 Seres Therapeutics Inc Earnings Call Transcript

Aug 03, 2022 / 12:30PM GMT
Release Date Price: $4.45 (+8.54%)
Operator

Good day, and thank you for standing by. Welcome to the Q2 2022 Seres Therapeutics, Inc. Earnings Conference Call. I will now turn the conference over to Dr. Carlo Tanzi, Investor Relations.

Carlo Tanzi
Seres Therapeutics, Inc. - IR Officer

Thank you, and good morning. Our press release for the company's second quarter 2022 financial results and a business update became available at 7:00 a.m. Eastern Time this morning and can be found on the Investors and News section of the company's website. I'd like to remind you that we'll be making forward-looking statements including the potential approval of SER-109 and its status as a first-in-class therapeutic, the timing of a BLA filing and potential product launch, the market for SER-109, the ultimate safety and efficacy data for our products, the use of cash to fund operations and other statements which are not historical facts. Actual results may differ materially. Additionally, these statements are subject to certain risks and uncertainties which are discussed under the Risk Factors section of our recent SEC

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot